|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Change in unearned premiums reserve | |||||
| Net premiums earned | |||||
| Assumed Premiums | |||||
| Total net premiums earned | |||||
| SurancePlus fee income | |||||
| Realized gain on other investments | |||||
| Net investment and other income | |||||
| Interest and gain on redemption of Series A-1 preferred shares | |||||
| Interest and gain on redemption of loan receivable | |||||
| Unrealized loss on other investments | |||||
| Change in fair value of equity securities | |||||
| Total revenue | |||||
| Expenses | |||||
| Losses and loss adjustment expenses | |||||
| Policy acquisition costs and underwriting expenses | |||||
| General and administrative expenses | |||||
| Total expenses | |||||
| Loss before loss (income) attributable to tokenholders and non-controlling interests | |||||
| Loss (income) attributable to tokenholders | |||||
| Loss before income attributable to non-controlling interests | |||||
| Income attributable to non-controlling interests | |||||
| Net loss attributable to ordinary shareholders | |||||
| Loss per share attributable to ordinary shareholders | |||||
| Basic | |||||
| Diluted | |||||
| Weighted-average shares outstanding | |||||
| Basic | |||||
| Diluted | |||||
Loading...